• DDX11 is overexpressed in gemcitabine-resistant gallbladder cancer cells and tissues, correlating with poor prognosis.
• DDX11 knockdown suppresses GBC proliferation and tumor growth while restoring gemcitabine sensitivity.
• Mechanistically, DDX11 interacts with PARP1 to enhance PARylation, promoting DNA repair and chemoresistance.
• Combining gemcitabine with the PARP inhibitor olaparib shows synergistic anti-tumor effects, suggesting a novel therapeutic strategy.